m1A/m5C/m6A/m7G调控基因预测胃癌预后及免疫关联性

doi:10.3969/j.issn.1006-5725.2024.09.009

Abstract

Abstract:

Objective This study aims to develop a prognostic risk prediction model for gastric cancer based on m1A/m5C/m6A/m7G regulated genes and to investigate the relationship between this model and immunology. Methods The Cancer Genome Atlas （TCGA） gastric cancer dataset was utilized to identify m1A/m5C/m6A/m7G regulated genes with significant expression differences. A prognostic risk score （RS） model was constructed using univariate Cox regression analysis and the LASSO algorithm. The RS model was validated using the Kaplan?Meier （K?M） statistic and cell lines for RT?qPCR biological validation. A nomogram model was created using univariate and multivariate Cox regression analyses. The CIBERSORT algorithm and ESTIMATE package were employed to conduct immune correlation analysis. Results A prognostic RS model based on eight methylation regulated genes was developed to classify patients with gastric cancer as high?risk or low?risk. These eight genes showed significant expression in gastric cancer cell lines （P < 0.05）. The TCGA?gastric cancer training set and GSE62254?validation set showed a substantial connection （P < 0.001） between overall survival rate （OS） and grouping status. The nomogram survival models accurately predicted 1?year （C?index = 0.703）， 3?year （C?index = 0.729）， and 5?year （C?index = 0.734） survival rates. Immune correlation analysis showed that compared to the low?risk group， the high?risk group had higher immune scores and higher expression of immune checkpoint?related genes （P < 0.05）. Conclusion We created a reliable prognostic RS model based on m1A/m5C/m6A/m7G regulated genes that can predict gastric cancer prognosis and guide individualized immunotherapy decisions.

Key words: m1A, m5C, m6A, m7G, gastric cancer, prognosis, immune infiltration

CLC Number:

R735.2

Xiaomei CHEN,Anqi WANG,Jizhen YANG,Miao YU. Prognosis and immune correlation analysis of m1A/m5C/m6A/m7G regulated genes in gastric cancer[J]. The Journal of Practical Medicine, 2024, 40(9): 1230-1237.

Figures/Tables 8

Fig.1

Fig.2

Fig.3

Fig.4

Tab.1

Fig.5

Fig.6

Fig.7

References 28

1	NACEV B A， JONES K B， INTLEKOFER A M， et al. The epigenomics of sarcoma［J］. Nat Rev Cancer， 2020，20（10）： 608-623. doi:10.1038/s41568-020-0288-4 doi: 10.1038/s41568-020-0288-4
2	SHI H， CHAI P， JIA R， et al. Novel insight into the regulatory roles of diverse RNA modifications： Re-defining the bridge between transcription and translation［J］. Mol Cancer， 2020，19（1）： 78. doi:10.1186/s12943-020-01194-6 doi: 10.1186/s12943-020-01194-6
3	HAN H， YANG C， MA J， et al. N（7）-methylguanosine tRNA modification promotes esophageal squamous cell carcinoma tumorigenesis via the RPTOR/ULK1/autophagy axis［J］. Nat Commun， 2022，13（1）： 1478. doi:10.1038/s41467-022-29125-7 doi: 10.1038/s41467-022-29125-7
4	LI N， ZENG A， WANG Q， et al. Regulatory function of DNA methylation mediated lncRNAs in gastric cancer［J］. Cancer Cell Int， 2022，22（1）： 227. doi:10.1186/s12935-022-02648-1 doi: 10.1186/s12935-022-02648-1
5	BINNEWIES M， ROBERTS E W， KERSTEN K， et al. Understanding the tumor immune microenvironment （TIME） for effective therapy［J］. Nat Med， 2018，24（5）： 541-550. doi:10.1038/s41591-018-0014-x doi: 10.1038/s41591-018-0014-x
6	XU L， ZOU C， ZHANG S， et al. Reshaping the systemic tumor immune environment （STIE） and tumor immune microenvironment （TIME） to enhance immunotherapy efficacy in solid tumors［J］. J Hematol Oncol， 2022，15（1）： 87. doi:10.1186/s13045-022-01307-2 doi: 10.1186/s13045-022-01307-2
7	LI N， KANG Y， WANG L， et al. ALKBH5 regulates anti-PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment［J］. Proc Natl Acad Sci U S A， 2020，117（33）： 20159-20170. doi:10.1073/pnas.1918986117 doi: 10.1073/pnas.1918986117
8	OH S C， SOHN B H， CHEONG J H， et al. Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype［J］. Nat Commun， 2018，9（1）： 1777. doi:10.1038/s41467-018-04179-8 doi: 10.1038/s41467-018-04179-8
9	CHEN Y， LIN H， MIAO L， et al. Role of N7-methylguanosine （m⁷G） in cancer［J］. Trends Cell Biol， 2022，32（10）： 819-824. doi:10.1016/j.tcb.2022.07.001 doi: 10.1016/j.tcb.2022.07.001
10	LI D， LI K， ZHANG W， et al. The m6A/m5C/m1A Regulated Gene Signature Predicts the Prognosis and Correlates With the Immune Status of Hepatocellular Carcinoma［J］. Front Immunol， 2022，13： 918140. doi:10.3389/fimmu.2022.918140 doi: 10.3389/fimmu.2022.918140
11	YANG B， WANG J Q， TAN Y， et al. RNA methylation and cancer treatment［J］. Pharmacol Res， 2021，174： 105937. doi:10.1016/j.phrs.2021.105937 doi: 10.1016/j.phrs.2021.105937
12	WANG X， TIAN L， LI Y， et al. RBM15 facilitates laryngeal squamous cell carcinoma progression by regulating TMBIM6 stability through IGF2BP3 dependent［J］. J Exp Clin Cancer Res， 2021，40（1）： 80. doi:10.1186/s13046-021-01871-4 doi: 10.1186/s13046-021-01871-4
13	CAI X， CHEN Y， MAN D， et al. RBM15 promotes hepatocellular carcinoma progression by regulating N6-methyladenosine modification of YES1 mRNA in an IGF2BP1-dependent manner［J］. Cell Death Discov， 2021，7（1）： 315. doi:10.1038/s41420-021-00703-w doi: 10.1038/s41420-021-00703-w
14	WANG Q， ZHANG Q， HUANG Y， et al. m（1）A Regulator TRMT10C Predicts Poorer Survival and Contributes to Malignant Behavior in Gynecological Cancers［J］. DNA Cell Biol， 2020，39（10）： 1767-1778. doi:10.1089/dna.2020.5624 doi: 10.1089/dna.2020.5624
15	ZHANG Q， YAN Y F， LV Q， et al. miR-4293 upregulates lncRNA WFDC21P by suppressing mRNA-decapping enzyme 2 to promote lung carcinoma proliferation［J］. Cell Death Dis， 2021，12（8）： 735. doi:10.1038/s41419-021-04021-y doi: 10.1038/s41419-021-04021-y
16	CHEN D， ZHANG R， XIE A， et al. Clinical correlations and prognostic value of Nudix hydroxylase 10 in patients with gastric cancer［J］. Bioengineered， 2021，12（2）： 9779-9789. doi:10.1080/21655979.2021.1995104 doi: 10.1080/21655979.2021.1995104
17	GRISANZIO C， WERNER L， TAKEDA D， et al. Genetic and functional analyses implicate the NUDT11， HNF1B， and SLC22A3 genes in prostate cancer pathogenesis［J］. Proc Natl Acad Sci U S A， 2012，109（28）： 11252-11257. doi:10.1073/pnas.1200853109 doi: 10.1073/pnas.1200853109
18	XIA P， ZHANG H， XU K， et al. MYC-targeted WDR4 promotes proliferation， metastasis， and sorafenib resistance by inducing CCNB1 translation in hepatocellular carcinoma［J］. Cell Death Dis， 2021，12（7）： 691. doi:10.1038/s41419-021-03973-5 doi: 10.1038/s41419-021-03973-5
19	LI X Y， WANG S L， CHEN D H， et al. Construction and Validation of a m7G-Related Gene-Based Prognostic Model for Gastric Cancer［J］. Front Oncol， 2022，12： 861412. doi:10.3389/fonc.2022.861412 doi: 10.3389/fonc.2022.861412
20	YANG S， LIU T， CHENG Y， et al. Immune cell infiltration as a biomarker for the diagnosis and prognosis of digestive system cancer［J］. Cancer Sci， 2019，110（12）： 3639-3649. doi:10.1111/cas.14216 doi: 10.1111/cas.14216
21	XU C， SUI S， SHANG Y， et al. The landscape of immune cell infiltration and its clinical implications of pancreatic ductal adenocarcinoma［J］. J Adv Res， 2020，24： 139-148. doi:10.1016/j.jare.2020.03.009 doi: 10.1016/j.jare.2020.03.009
22	EISSMANN M F， DIJKSTRA C， JARNICKI A， et al. IL-33-mediated mast cell activation promotes gastric cancer through macrophage mobilization［J］. Nat Commun， 2019，10（1）： 2735. doi:10.1038/s41467-019-10676-1 doi: 10.1038/s41467-019-10676-1
23	LICHTERMAN J N， REDDY S M. Mast Cells： A New Frontier for Cancer Immunotherapy［J］. Cells， 2021，10（6）： 1270. doi:10.3390/cells10061270 doi: 10.3390/cells10061270
24	WANG P， WANG H， HUANG Q， et al. Exosomes from M1-Polarized Macrophages Enhance Paclitaxel Antitumor Activity by Activating Macrophages-Mediated Inflammation［J］. Theranostics， 2019，9（6）： 1714-1727. doi:10.7150/thno.30716 doi: 10.7150/thno.30716
25	CENDROWICZ E， SAS Z， BREMER E， et al. The Role of Macrophages in Cancer Development and Therapy［J］. Cancers （Basel）， 2021，13（8）： 1946. doi:10.3390/cancers13081946 doi: 10.3390/cancers13081946
26	YU D， WALKER L， LIU Z， et al. Targeting T（FH） cells in human diseases and vaccination： rationale and practice［J］. Nat Immunol， 2022，23（8）： 1157-1168. doi:10.1038/s41590-022-01253-8 doi: 10.1038/s41590-022-01253-8
27	GONG Z， ZHANG J， GUO W. Tumor purity as a prognosis and immunotherapy relevant feature in gastric cancer［J］. Cancer Med， 2020，9（23）： 9052-9063. doi:10.1002/cam4.3505 doi: 10.1002/cam4.3505
28	ZENG D， ZHOU R， YU Y， et al. Gene expression profiles for a prognostic immunoscore in gastric cancer［J］. Br J Surg， 2018，105（10）： 1338-1348. doi:10.1002/bjs.10871 doi: 10.1002/bjs.10871

临床特征	单因素Cox回归			多因素Cox回归
临床特征	HR	95%CI	P值	HR	95%CI	P值
年龄（x ± s，年）	1.022	1.006 ~ 1.039	7.42E?03	1.039	1.017 ~ 1.062	5.680E?04
性别（男/女）	1.271	0.891 ~ 1.811	1.86E?01	-	-	-
病理M分期（M0/M1/-）	2.509	1.440 ~ 4.370	7.73E?04	1.015	0.430 ~ 2.395	9.732E?01
病理N分期（N0/N1/N2/N3/-）	1.335	1.149 ~ 1.550	1.29E?04	1.089	0.867 ~ 1.369	4.621E?01
病理T分期（T1/T2/T3/T4/-）	1.317	1.070 ~ 1.620	9.23E?03	1.052	0.783 ~ 1.412	7.375E?01
病理分期（Ⅰ/Ⅱ/Ⅲ/Ⅳ/-）	1.599	1.301 ~ 1.966	6.86E?06	1.429	1.065 ~ 1.919	1.730E?02
组织学分级（G1/G2/G3/-）	1.378	0.998 ~ 1.903	5.04E?02	-	-	-
放射治疗（Yes/No/-）	0.428	0.261 ~ 0.701	5.35E?04	0.411	0.215 ~ 0.788	7.372E?03
幽门螺杆菌感染（Yes/No/-）	1.042	0.275 ~ 1.491	2.98E?01	-	-	-
复发（Yes/No/-）	2.627	1.752 ~ 3.939	1.21E?06	2.941	1.841 ~ 4.696	6.290E?06
RS模型状态（High/Low）	1.805	1.286 ~ 2.533	5.32E?04	1.881	1.279 ~ 2.763	1.300E?03

[1]	Shihe XIAO,Gang LI,Zhonghai LIU,Zhen. LIU. Expression of ZEB2 and CCL20 in glioma tissue and their correlation with prognosis [J]. The Journal of Practical Medicine, 2024, 40(9): 1262-1267.
[2]	Futao DANG,Yingmei TANG,Haiyan FU,Huanlong LI,Jiamin XU,Xu. TAN. The efficacy of artificial （nonbiological） extracorporeal liver support system for primary biliary cholangitis and the effect of this therapy on prognosis [J]. The Journal of Practical Medicine, 2024, 40(7): 955-961.
[3]	Xiya MA,Hu JI,Zehua ZHU,Bo PAN,Qiang XIE,Xiaobo. YAO. The predictive value of ¹⁸F⁃FDG PET/CT metabolic heterogeneity parameters combined with clinical features for the prognosis of esophageal squamous cell carcinoma before definitive radiochemotherapy [J]. The Journal of Practical Medicine, 2024, 40(7): 966-971.
[4]	Yuxin CHENG,Liang LIU,Shiyu DONG,Shengchao LI,Meng ZHANG. Research advances in exosomal proteins， mRNA and non⁃coding RNA regulation of Hepatocellular Carcinoma [J]. The Journal of Practical Medicine, 2024, 40(6): 748-755.
[5]	Jianliang YAN,Zeyu XIE,Rongrong JING,Ming. CUI. Research on establishing gastric cancer lymph node metastasis prediction model based on machine learning and routine laboratory indicators [J]. The Journal of Practical Medicine, 2024, 40(6): 844-849.
[6]	Shu CHEN,Jinglei ZHANG,Kang RONG,Nan ZHANG,Weiyi SUN. Research progress of exosomes in distant metastasis and drug resistance of gastric cancer [J]. The Journal of Practical Medicine, 2024, 40(6): 870-876.
[7]	Sibo LONG,Yan CHEN,Xintong ZHANG,Yanjun YIN,Limei YANG,Maike ZHENG,Chaohong WANG,Qing SUN,Jun YAN,Yiheng SHI,Guangli SHI,Yan ZHAO,Guirong. WANG. Serum levels of procalcitonin， interleukin⁃6 and interleukin⁃8 in patients with COVID⁃19 infection at admission and their significance in patient prognosis [J]. The Journal of Practical Medicine, 2024, 40(4): 471-475.
[8]	Li XU,Shanshan HU,Haiming. ZHAO. LncRNA GNAS⁃AS1 participates in the proliferation and migration of gastric cancer cells by regulating the miR⁃449a/Notch1 axis [J]. The Journal of Practical Medicine, 2024, 40(4): 483-489.
[9]	Zixu SONG,Guangzheng ZHU,Chenxu GUO,Jiaqi WU,Ligong ZHANG,Jun. QIAN. Expression of SLC35A2 and PFDN2 in breast cancer and its relationship with clinical observables and prognosis [J]. The Journal of Practical Medicine, 2024, 40(4): 496-502.
[10]	Yichen WANG,Yanwen YAN,Meihui SONG,Xiangjun XUE,Wenguang ZHOU,Yuquan LI,Ling QI,Guanghua LI,Xiangzong ZENG. Clinical significance of HOXB4 gene expression levels in myelodysplastic syndromes [J]. The Journal of Practical Medicine, 2024, 40(3): 321-325.
[11]	Jia CUI,Mingming ZHANG,Na WANG,Wei GAO,Fei LI. Correlation analysis of glucose and lipid metabolism indicators combined with antiphospholipid antibodies on prognosis of patients with atherosclerosis [J]. The Journal of Practical Medicine, 2024, 40(3): 326-329.
[12]	Shuang CHEN,Na YANG,Yudong HUANG,Xiangfeng KONG,Jintao LI,Yizhong TANG,Kexiong MA,Yangyang ZHANG,Yuandong ZHANG,Chengde REN. Relationship between serum miR-21 and miR-27b levels and prognosis of patients with renal clear cell carcinoma [J]. The Journal of Practical Medicine, 2024, 40(3): 343-348.
[13]	Jian ZHAO,Songjie LIU,Guanchao ZHANG,Yuhou SHEN,Fengchen LI,Bing XU. Expression of CENPF and miR⁃1⁃3p in the serum of patients with advanced gastric cancer and their correlation with prognosis [J]. The Journal of Practical Medicine, 2024, 40(3): 365-370.
[14]	Zhijie XIA,Jun LI,Qian GAO,Zhicheng LI,Zhongfang. XIA. Effect and prognosis of preauricular fistula treated by double⁃incision tunnel combined with preauricular tissue and cartilage resection [J]. The Journal of Practical Medicine, 2024, 40(22): 3179-3183.
[15]	Chengcai DAI,Zhenxing CHENG,Qianqian TU. The prognostic value of serum cystatin C combined with bedside renal ultrasound in patients with sepsis⁃induced acute kidney injury [J]. The Journal of Practical Medicine, 2024, 40(22): 3226-3231.

Prognosis and immune correlation analysis of m1A/m5C/m6A/m7G regulated genes in gastric cancer

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 8

References 28

Related Articles 15

Recommended Articles

Metrics

Comments